Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver


Kaya E., Yılmaz Y.

Journal of Clinical and Translational Hepatology, vol.10, no.2, pp.329-338, 2022 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 10 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.14218/jcth.2021.00178
  • Journal Name: Journal of Clinical and Translational Hepatology
  • Journal Indexes: Science Citation Index Expanded
  • Page Numbers: pp.329-338
  • Keywords: Metabolic diseases, Fatty liver, Liver fibrosis, Diabetes mellitus, type 2, Cardiometabolic risk factors, OBSTRUCTIVE SLEEP-APNEA, CHRONIC KIDNEY-DISEASE, INDEPENDENT RISK-FACTOR, NONALCOHOLIC STEATOHEPATITIS, CARDIOVASCULAR-DISEASE, INCREASED PREVALENCE, FIBROSIS STAGE, NAFLD, SEVERITY, DYSFUNCTION

Abstract

© 2022 The Author(s).Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents with a wide spectrum of ex-trahepatic manifestations, such as obesity, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, chronic kidney disease, extrahepatic malignancies, cognitive disorders, and polycystic ovarian syndrome. Among NAFLD patients, the most common mortality etiology is cardiovascular disorders, followed by extrahepatic malig-nancies, diabetes mellitus, and liver-related complications. Furthermore, the severity of extrahepatic diseases is parallel to the severity of NAFLD. In clinical practice, aware-ness of the associations of concomitant diseases is of major importance for initiating prompt and timely screening and multidisciplinary management of the disease spectrum. In 2020, a consensus from 22 countries redefined the disease as metabolic (dysfunction)-associated fatty liver disease (MAFLD), which resulted in the redefinition of the corre-sponding population. Although the patients diagnosed with MAFLD and NAFLD mostly overlap, the MAFLD and NAFLD populations are not identical. In this review, we compared the associations of key extrahepatic diseases between NAFLD and MAFLD.